Gain Therapeutics, Inc. (GANX)

Gain Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	0.06	0.14	0.16
Revenue Growth (YoY)	-	-	-60.62%	-15.08%	471.29%
Gross Profit	-	-	0.06	0.14	0.16
Selling, General & Admin	8.5	9.56	10.79	9.54	6.83
Research & Development	10.21	10.79	11.52	8.38	7.16
Total Operating Expenses	18.71	20.35	22.31	17.92	13.99
Operating Income	-18.71	-20.35	-22.25	-17.78	-13.83
Interest Income	0.24	0.36	0.49	0.38	0.01
Other Non-Operating Income (Expense)	-0.83	0.12	-0.43	-0.1	-0.07
Total Non-Operating Income (Expense)	-0.59	0.48	0.06	0.28	-0.06
Pretax Income	-19.3	-19.87	-22.19	-17.5	-13.89
Provision for Income Taxes	0.86	0.54	0.08	0.09	0
Net Income	-20.16	-20.41	-22.27	-17.59	-13.89
Net Income to Common	-20.16	-20.41	-22.27	-17.59	-13.89
Shares Outstanding (Basic)	33	23	13	12	10
Shares Outstanding (Diluted)	33	23	13	12	10
Shares Change (YoY)	44.08%	75.86%	9.49%	16.90%	279.11%
EPS (Basic)	-0.61	-0.89	-1.71	-1.48	-1.37
EPS (Diluted)	-0.61	-0.89	-1.71	-1.48	-1.37
Shares Outstanding	36.1	27.13	16.21	11.88	11.88
Free Cash Flow	-18.47	-18.9	-18.88	-14.81	-12.46
Free Cash Flow Per Share	-0.56	-0.83	-1.45	-1.25	-1.23
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-40328.26%	-12688.10%	-8379.80%
Profit Margin	-	-	-40354.33%	-12555.13%	-8418.86%
FCF Margin	-	-	-34217.53%	-10571.20%	-7551.72%
EBITDA	-18.62	-20.27	-22.17	-17.71	-13.81
EBITDA Margin	-	-	-40176.79%	-12642.30%	-8370.42%
EBIT	-18.71	-20.35	-22.25	-17.78	-13.83
EBIT Margin	-	-	-40328.26%	-12688.10%	-8379.80%
Effective Tax Rate	-4.46%	-2.70%	-0.36%	-0.53%	-0.03%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q